MyFinsight
Home
Blog
About
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$45,655K
Free Cash flow
-$58,561K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturity of market...
Stock-based compensation expense
Accounts payable, accrued liabil...
Others
Negative Cash Flow Breakdown
Net (loss) income
Purchases of marketable securiti...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net (loss) income
-61,618
-50,003
-57,934
-38,348
Depreciation
458
439
405
442
Amortization and accretion of marketable securities
-369
-365
-551
-615
Stock-based compensation expense
10,802
8,753
9,848
8,039
Impairment of right of use asset
-
-
0
696
Loss on disposal of property and equipment
-
-
-153
8
Reduction in the carrying amount of right of use assets
680
608
650
547
Accounts receivable
2,729
-1,486
-3,312
7,580
Prepaid expenses and other current assets
3,913
3,588
-220
-5,640
Accounts payable, accrued liabilities and lease liabilities
2,598
-15,719
8,902
4,881
Deferred revenue
-2,494
-2,193
4,541
-4,060
Net cash (used in) provided by operating activities
-56,585
-60,582
-30,454
-30,366
Purchases of property and equipment
1,976
353
232
132
Purchases of marketable securities
36,106
9,853
98,228
23,925
Proceeds from maturity of marketable securities
47,100
60,900
37,399
33,151
Net cash provided by (used in) investing activities
9,018
50,694
-61,061
9,094
Proceeds from employee stock purchase plan
0
465
0
632
Proceeds from issuance of common stock upon exercise of stock options
1,912
3,205
4,557
2,488
Proceeds from controlled equity offering sales agreement, net of commissions
-
-
87,784
-
Proceeds from issuance of common stock in controlled equity offering sales agreements
0
80,657
-
-
Net cash provided by financing activities
1,912
84,327
92,341
3,120
Net increase in cash, cash equivalents and restricted cash
-45,655
74,439
826
-18,152
Cash, cash equivalents and restricted cashbeginning of period
159,380
84,941
84,115
128,779
Cash, cash equivalents and restricted cashend of period
113,725
159,380
84,941
84,115
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturity of
marketable securities
$47,100K
(-28.67%↓ Y/Y)
Proceeds from issuance of
common stock upon...
$1,912K
(22.72%↑ Y/Y)
Net cash provided by
(used in) investing...
$9,018K
(106.69%↑ Y/Y)
Net cash provided by
financing activities
$1,912K
(-0.83%↓ Y/Y)
Canceled cashflow
$38,082K
Net increase in
cash, cash...
-$45,655K
(-72.21%↓ Y/Y)
Canceled cashflow
$10,930K
Stock-based compensation
expense
$10,802K
(-24.73%↓ Y/Y)
Accounts payable,
accrued liabilities and...
$2,598K
(-65.39%↓ Y/Y)
Reduction in the carrying
amount of right of use...
$680K
(-43.85%↓ Y/Y)
Depreciation
$458K
(-50.38%↓ Y/Y)
Purchases of marketable
securities
$36,106K
(-82.00%↓ Y/Y)
Purchases of property and
equipment
$1,976K
(545.75%↑ Y/Y)
Net cash (used in)
provided by operating...
-$56,585K
(-153.18%↓ Y/Y)
Canceled cashflow
$14,538K
Net (loss) income
-$61,618K
(-168.93%↓ Y/Y)
Prepaid expenses and
other current assets
$3,913K
(-38.91%↓ Y/Y)
Accounts receivable
$2,729K
Deferred revenue
-$2,494K
(-308.18%↓ Y/Y)
Amortization and accretion of
marketable securities
-$369K
(-1218.18%↓ Y/Y)
Buy us a coffee